Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837814 | 0.84 | CHRM4 (0.42) | CHRM4DRD2DRD3L3MBTL3L3MBTL1 | |
| SCHEMBL3440736 | 0.84 | MAPT (0.46) | CHRM4L3MBTL1HRH3 | |
| SCHEMBL22837878 | 0.83 | MBTD1 (0.47) | CHRM4DRD2DRD3ACHEMBTD1 | |
| SCHEMBL10118638 | 0.78 | MEN1 (0.53) | HRH3 | |
| SCHEMBL15037944 | 0.78 | DPP4 (0.60) | CHRM4DRD2DRD3MBTD1L3MBTL3 | |
| SCHEMBL18155147 | 0.77 | MBTD1 (0.49) | CHRM4DRD2DRD3ACHEMBTD1 | |
| SCHEMBL4705716 | 0.77 | MBTD1 (0.49) | CHRM4DRD2DRD3ACHEMBTD1 | |
| SCHEMBL4703341 | 0.77 | CYP2D6 (0.50) | CHRM4ACHEMBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL424881 | 0.77 | CHRNA7 (0.55) | DRD2ACHEMBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL12092567 | 0.77 | NOTUM (0.46) | DRD2DRD3ACHEMBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | CHRM4 3273/4885DRD2 2283/4885DRD3 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.